{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T23:23:59Z","timestamp":1772753039417,"version":"3.50.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2013,2,1]],"date-time":"2013-02-01T00:00:00Z","timestamp":1359676800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1016\/j.ygyno.2012.07.126","type":"journal-article","created":{"date-parts":[[2012,8,9]],"date-time":"2012-08-09T16:20:36Z","timestamp":1344529236000},"page":"215-220","source":"Crossref","is-referenced-by-count":38,"title":["A phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinoma"],"prefix":"10.1016","volume":"128","author":[{"given":"Susana M.","family":"Campos","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard T.","family":"Penson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ursula","family":"Matulonis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil S.","family":"Horowitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christin","family":"Whalen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karin","family":"Tyburski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Roche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jackie","family":"Szymonifka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suzanne","family":"Berlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ygyno.2012.07.126_bb0005","series-title":"Cancer, Principles and Practice of Oncology","article-title":"Ovarian cancer, fallopian tube carcinoma and peritoneal carcinoma","author":"Ozols","year":"1997"},{"key":"10.1016\/j.ygyno.2012.07.126_bb0010","doi-asserted-by":"crossref","first-page":"3312","DOI":"10.1200\/JCO.2001.19.14.3312","article-title":"Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan","volume":"19","author":"Gordon","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2012.07.126_bb0015","first-page":"276","article-title":"Vascular permeability factor gene expression in normal and neoplastic human ovaries","volume":"54","author":"Olson","year":"1994","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2012.07.126_bb0020","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.4161\/cbt.6.12.4976","article-title":"PDGF BB induces VEGF secretion in ovarian cancer","volume":"6","author":"Matei","year":"2007","journal-title":"Cancer Biol Ther"},{"key":"10.1016\/j.ygyno.2012.07.126_bb0025","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1038\/sj.onc.1209232","article-title":"Autocrine activation of PDGFRalpha promotes the progression of ovarian cancer","volume":"25","author":"Matei","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.ygyno.2012.07.126_bb0030","first-page":"4550","article-title":"Expression and prognostic significance of platelet-derived growth factor and its receptors in epithelial ovarian neoplasms","volume":"53","author":"Henriksen","year":"1993","journal-title":"Cancer Res"},{"key":"10.1016\/j.ygyno.2012.07.126_bb0035","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1096\/fj.03-0271fje","article-title":"Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms","volume":"18","author":"Erber","year":"2004","journal-title":"FASEB J"},{"key":"10.1016\/j.ygyno.2012.07.126_bb0040","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1200\/JCO.2007.11.5345","article-title":"Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study","volume":"25","author":"Burger","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2012.07.126_bb0045","doi-asserted-by":"crossref","first-page":"5180","DOI":"10.1200\/JCO.2007.12.0782","article-title":"Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer","volume":"25","author":"Cannistra","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2012.07.126_bb0050","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1200\/JCO.2007.12.1939","article-title":"Phase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortia","volume":"26","author":"Garcia","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2012.07.126_bb0055","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1002\/cncr.21969","article-title":"Bevacizumab combination therapy in recurrent, platinum-refractory, epithelial ovarian carcinoma: a retrospective analysis","volume":"107","author":"Wright","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2012.07.126_bb0060","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ygyno.2007.07.017","article-title":"Bevacizumab plus cyclophosphamide in heavily pretreated patients with recurrent ovarian cancer","volume":"107","author":"Chura","year":"2007","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2012.07.126_bb0065","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.ygyno.2008.02.009","article-title":"Efficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II Consortia","volume":"110","author":"Nimeiri","year":"2008","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2012.07.126_bb0070","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.ygyno.2006.05.006","article-title":"Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer","volume":"102","author":"Monk","year":"2006","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2012.07.126_bb0075","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1200\/JCO.2009.22.7900","article-title":"Phase II study of carboplatin, paclitaxel, and bevacizumab with maintenance bevacizumab as first-line chemotherapy for advanced Mullerian tumors","volume":"28","author":"Penson","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2012.07.126_bb0080","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2012.07.126_bb0085","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ygyno.2012.07.126_bb0090","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1038\/nrclinonc.2009.130","article-title":"An overview of small-molecule inhibitors of VEGFR signaling","volume":"6","author":"Ivy","year":"2009","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ygyno.2012.07.126_bb0095","doi-asserted-by":"crossref","first-page":"5601","DOI":"10.1200\/JCO.2009.23.2777","article-title":"Cediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancer","volume":"27","author":"Matulonis","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2012.07.126_bb0100","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ygyno.2010.05.033","article-title":"A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer","volume":"119","author":"Friedlander","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2012.07.126_bb0105","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1200\/JCO.2009.26.7856","article-title":"Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a Gynecologic Oncology Group trial","volume":"29","author":"Matei","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2012.07.126_bb0110","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ygyno.2011.06.019","article-title":"Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: a phase II study","volume":"123","author":"Bodnar","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2012.07.126_bb0115","doi-asserted-by":"crossref","first-page":"3798","DOI":"10.1200\/JCO.2010.33.5208","article-title":"Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer","volume":"29","author":"Ledermann","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2012.07.126_bb0120","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.ygyno.2010.11.035","article-title":"Overview of anti-angiogenic agents in development for ovarian cancer","volume":"121","author":"Burger","year":"2011","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ygyno.2012.07.126_bb0125","first-page":"327","article-title":"In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic\/pharmacodynamic relationship","volume":"9","author":"Mendel","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2012.07.126_bb0130","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1200\/JCO.2005.02.2574","article-title":"Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma","volume":"24","author":"Motzer","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2012.07.126_bb0135","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1158\/1078-0432.CCR-06-2328","article-title":"Approval summary: sunitinib for the treatment of imatinib refractory or intolerant gastrointestinal stromal tumors and advanced renal cell carcinoma","volume":"13","author":"Goodman","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ygyno.2012.07.126_bb0140","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1200\/JCO.2007.14.5375","article-title":"Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane","volume":"26","author":"Burstein","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2012.07.126_bb0145","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"Raymond","year":"2011","journal-title":"New England Journal of Medicine"},{"key":"10.1016\/j.ygyno.2012.07.126_bb0150","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1093\/annonc\/mdq357","article-title":"A phase II study of sunitinib in patients with recurrent epithelial ovarian and primary peritoneal carcinoma: an NCIC Clinical Trials Group Study","volume":"22","author":"Biagi","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ygyno.2012.07.126_bb0155","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1016\/j.ejca.2009.02.011","article-title":"Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure","volume":"45","author":"George","year":"2009","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ygyno.2012.07.126_bb0160","author":"Baumann","year":"2012","journal-title":"Ann Oncol."},{"key":"10.1016\/j.ygyno.2012.07.126_bb0180","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1634\/theoncologist.2009-0235","article-title":"Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies","volume":"15","author":"Girardi","year":"2010","journal-title":"Oncologist"},{"key":"10.1016\/j.ygyno.2012.07.126_bb0185","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1113\/jphysiol.2006.109389","article-title":"AMPK alterations in cardiac physiology and pathology: enemy or ally?","volume":"574","author":"Dyck","year":"2006","journal-title":"J Physiol"},{"key":"10.1016\/j.ygyno.2012.07.126_bb0190","doi-asserted-by":"crossref","first-page":"9554","DOI":"10.1128\/MCB.25.21.9554-9575.2005","article-title":"AMP-activated protein kinase protects cardiomyocytes against hypoxic injury through attenuation of endoplasmic reticulum stress","volume":"25","author":"Terai","year":"2005","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.ygyno.2012.07.126_bb0195","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3109\/02841860903524396","article-title":"Risk of cardiac ischemia and arterial thromboembolic events with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis of randomized controlled trials","volume":"49","author":"Ranpura","year":"2010","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ygyno.2012.07.126_bb0200","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2011.29.18_suppl.lba5007","article-title":"OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"29","author":"Aghajanian","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2012.07.126_bb0205","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/sj.bjc.6605483","article-title":"Biomarkers of angiogenesis and their role in the development of VEGF inhibitors","volume":"102","author":"Murukesh","year":"2010","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ygyno.2012.07.126_bb0210","doi-asserted-by":"crossref","first-page":"4672","DOI":"10.1200\/JCO.2008.16.1612","article-title":"Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100","volume":"26","author":"Schneider","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ygyno.2012.07.126_bb0215","doi-asserted-by":"crossref","first-page":"7554","DOI":"10.1158\/1078-0432.CCR-08-0351","article-title":"Polymorphisms and clinical outcome in recurrent ovarian cancer treated with cyclophosphamide and bevacizumab","volume":"14","author":"Schultheis","year":"2008","journal-title":"Clin Cancer Res"}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082581200652X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082581200652X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,7,2]],"date-time":"2019-07-02T14:00:58Z","timestamp":1562076058000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009082581200652X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["S009082581200652X"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2012.07.126","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2013,2]]}}}